Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer

por Ismail, R.K., van Breeschoten, J., Wouters, M.W.J.M., van Dartel, M., van der Flier, S., Reyners, A.K.L., de Graeff, P., Pasmooij, A.M.G., de Boer, A., Broekman, K.E., Hilarius, D.L.
Publicado 2021

Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?

por Ismail, R.K., van Breeschoten, J., Wouters, M.W.J.M., van Dartel, M., van der Flier, S., Reyners, A.K.L., de Graeff, P., Pasmooij, A.M.G., de Boer, A., Broekman, K.E., Hilarius, D.L.
Publicado 2022

Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC

por Ismail, R. K., Schramel, F. M. N. H., van Dartel, M., Pasmooij, A. M. G., Cramer-van der Welle, C. M., Hilarius, D. L., de Boer, A., Wouters, M. W. J. M., van de Garde, E. M. W.
Publicado 2023

Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC

por Ismail, R. K., Schramel, F. M. N. H., van Dartel, M., Pasmooij, A. M. G., der Welle, C. M. Cramer-van, Hilarius, D. L., de Boer, A., Wouters, M. W. J. M., van de Garde, E. M. W.
Publicado 2023